FDA clears Novavax to resume trials for combined COVID-19 and flu vaccine after safety review.

The FDA has lifted the clinical hold on Novavax's combination COVID-19 and influenza vaccine and its standalone flu vaccine. The hold was placed after a participant experienced motor neuropathy symptoms, but the FDA determined these symptoms were unrelated to the vaccine. Novavax plans to resume its Phase 3 trial, and the company's stock price increased by over 13% in response to the FDA's decision.

November 11, 2024
18 Articles